Pharsight

Triumeq Pd patents expiration

TRIUMEQ PD's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(5 years from now)

Triumeq Pd is owned by Viiv Hlthcare.

Triumeq Pd contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.

Triumeq Pd has a total of 4 drug patents out of which 0 drug patents have expired.

Triumeq Pd was authorised for market use on 30 March, 2022.

Triumeq Pd is available in tablet, for suspension;oral dosage forms.

The generics of Triumeq Pd are possible to be released after 08 June, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 15, 2026
Pediatric Exclusivity(PED) Dec 15, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 30 March, 2022

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TRIUMEQ PD before it's drug patent expiration?
More Information on Dosage

TRIUMEQ PD family patents

Family Patents